Clinical trial
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) (ELEVATE)
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP) (ELEVATE)
ClinicalTrials.gov ID: NCT04883905
Sponsor: Alnylam Pharmaceuticals
Information provided by: Alnylam Pharmaceuticals (Responsible Party)
Last Update Posted: 2023-11-15
Brief Summary:
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Official Title:
ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP)
| Category | Value |
|---|---|
| Study Start (Actual) | 2021-04-26 |
| Primary Completion (Estimated) |
2027-04
|
| Study Completion (Estimated) | 2027-04 |
| Enrollment (Estimated) | 150 |
| Study Type | Observational |
| Other Study ID Numbers |
ALN-AS1-006 |